Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin.
about
Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes.Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)Intracellular drug bioavailability: a new predictor of system dependent drug disposition.Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.Role of P-glycoprotein in statin drug interactions.Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone.Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers.Intestinal permeability and its relevance for absorption and elimination.Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability.The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins.Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium.Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.Renal Drug Transporters and Drug Interactions.Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents.Discovery of 4,4-Disubstituted Quinazolin-2-ones as T-Type Calcium Channel Antagonists.Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptor.Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients.Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport.Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malariaCommon genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males.Drug-drug interaction study to assess the effects of atorvastatin co-administration on pharmacokinetics and anti-thrombotic properties of cilostazol in male Wistar rats.ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.In vitro/in silico approach in the development of simvastatin-loaded self-microemulsifying drug delivery systems.The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition.
P2860
Q30234940-293ACAA3-A234-4941-8CE1-D54BF92ADE47Q33891588-73B7A2C9-A76A-41F2-BF5F-87BE722029EFQ34994901-E304D2BF-0F95-4A91-B4DD-0EAC72DAD77AQ36287236-8828ACA6-30FE-4A38-B8A4-88F2B72A482EQ36328417-4A43F5B0-4BAD-46CE-8BEB-4869508BE301Q36634221-BBF41982-2F0F-4F40-8042-3FE77F20F418Q36856634-2785B9CF-3D3A-4E56-9553-67826C72F874Q36912481-9F187FC6-2DD3-4EEC-9473-1516DE7D86F8Q36985043-572C64AD-5271-4061-84D9-7B1115E897EAQ37712256-8147DD98-D4C5-46A7-9DC7-5CEB72FF715AQ37810986-B1A6B775-10D4-4DC6-ACE8-59670C99FD8CQ37855801-074050FB-639E-41C2-ADDC-CD87D23FC232Q38050686-D004DEED-056C-4DD5-ABDC-69594BD75A73Q38099195-33A5C234-17DF-400C-8A87-B387887AF8C3Q38109095-10BF1383-88BF-41E6-AEF3-0086E62B4CEFQ39140289-7AB1069B-638C-490C-9D70-47E60B04CC4FQ39158082-FF7933C6-36E7-485E-AC24-168088A96D01Q39159599-6039E6F6-27F3-49F5-A106-BEC8D90FAA67Q39474573-A2003025-C0A9-4BC2-925C-AF708362FE7AQ39941183-37865859-B50D-43AF-B207-6CFF8D6625D8Q40230832-249C575D-30F6-44F2-BF49-1C68A04AB398Q40346102-A4045512-CB32-4A44-8CE4-E6334ADE37CCQ41938814-11E1A889-B15E-40DD-A662-D681E2616670Q43248042-732A6755-E2FE-4E95-A427-EC054D1F364DQ43574589-51FC7708-7E69-4E80-A5D9-236ADCC497B0Q46111557-D69F1331-27ED-493C-8FBC-7319FBD282DDQ48301397-73AB64DE-EB42-44F3-AB7F-59594B7A12C4Q48573264-2EC62EE1-909C-40DA-9E3A-2C4FAA15B852Q51082870-026B90A2-9FFF-4C77-837D-9FF4C1A06DD8
P2860
Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Interactions of human P-glycop ...... statin acid, and atorvastatin.
@en
type
label
Interactions of human P-glycop ...... statin acid, and atorvastatin.
@en
prefLabel
Interactions of human P-glycop ...... statin acid, and atorvastatin.
@en
P2093
P1476
Interactions of human P-glycop ...... statin acid, and atorvastatin.
@en
P2093
Cuyue Tang
Jerome H Hochman
Jiunn H Lin
Masayo Yamazaki
Nicole Pudvah
Thomayant Prueksaritanont
P304
P356
10.1023/B:PHAM.0000041466.84653.8C
P577
2004-09-01T00:00:00Z